Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice

Emanuela Palmerini, Kunhua Fan, Kan Yang, Mauro Risio, Winfried Edelmann, Martin Lipkin, Guido Biasco

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1 +/-/Apc1638N/+ mice, in a preclinical model of human colon cancer. Materials and Methods: Mice were fed AIN-76A diet alone or premixed with piroxicam (60 ppm) for 9 weeks. The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine. Results: Piroxicam reduced the number of tumors per mouse by 80% in the small intestine (0.1 vs. 0.5, p<0.05). In contrast, piroxicam increased tumor incidence (82% vs. 10%, p<0.01), tumor multiplicity (1.2 vs. 0.1, p<0.01) and tumor volume (2.1 vs. 0.2 mm3, p<0.01) in the colon. Apoptosis increased in the epithelium of the small intestine. Conclusion: Consistent with the increased apoptosis, piroxicam reduced tumors in the small intestine. In the cecum, piroxicam increased tumorigenesis but apoptosis was not decreased, suggesting that other mechanisms besides apoptosis are involved in the differential organ-specific effect on tumorigenesis of piroxicam in this colon cancer model.

Original languageEnglish (US)
Pages (from-to)3807-3812
Number of pages6
JournalAnticancer Research
Volume27
Issue number6 B
StatePublished - Nov 2007

Fingerprint

Piroxicam
Colon
Carcinogenesis
Apoptosis
Small Intestine
Neoplasms
Tumor Burden
Colonic Neoplasms
Cecum
Large Intestine
Mucous Membrane
Anti-Inflammatory Agents
Epithelium
Diet
Incidence
Pharmaceutical Preparations

Keywords

  • Apc
  • Apoptosis
  • Chemoprevention
  • Colon cancer
  • Mlh1
  • Non-steroidal anti-inflammatory drugs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Palmerini, E., Fan, K., Yang, K., Risio, M., Edelmann, W., Lipkin, M., & Biasco, G. (2007). Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice. Anticancer Research, 27(6 B), 3807-3812.

Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice. / Palmerini, Emanuela; Fan, Kunhua; Yang, Kan; Risio, Mauro; Edelmann, Winfried; Lipkin, Martin; Biasco, Guido.

In: Anticancer Research, Vol. 27, No. 6 B, 11.2007, p. 3807-3812.

Research output: Contribution to journalArticle

Palmerini, E, Fan, K, Yang, K, Risio, M, Edelmann, W, Lipkin, M & Biasco, G 2007, 'Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice', Anticancer Research, vol. 27, no. 6 B, pp. 3807-3812.
Palmerini E, Fan K, Yang K, Risio M, Edelmann W, Lipkin M et al. Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice. Anticancer Research. 2007 Nov;27(6 B):3807-3812.
Palmerini, Emanuela ; Fan, Kunhua ; Yang, Kan ; Risio, Mauro ; Edelmann, Winfried ; Lipkin, Martin ; Biasco, Guido. / Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice. In: Anticancer Research. 2007 ; Vol. 27, No. 6 B. pp. 3807-3812.
@article{86763495b4f14c3f9bce8134cca0d70d,
title = "Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice",
abstract = "Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1 +/-/Apc1638N/+ mice, in a preclinical model of human colon cancer. Materials and Methods: Mice were fed AIN-76A diet alone or premixed with piroxicam (60 ppm) for 9 weeks. The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine. Results: Piroxicam reduced the number of tumors per mouse by 80{\%} in the small intestine (0.1 vs. 0.5, p<0.05). In contrast, piroxicam increased tumor incidence (82{\%} vs. 10{\%}, p<0.01), tumor multiplicity (1.2 vs. 0.1, p<0.01) and tumor volume (2.1 vs. 0.2 mm3, p<0.01) in the colon. Apoptosis increased in the epithelium of the small intestine. Conclusion: Consistent with the increased apoptosis, piroxicam reduced tumors in the small intestine. In the cecum, piroxicam increased tumorigenesis but apoptosis was not decreased, suggesting that other mechanisms besides apoptosis are involved in the differential organ-specific effect on tumorigenesis of piroxicam in this colon cancer model.",
keywords = "Apc, Apoptosis, Chemoprevention, Colon cancer, Mlh1, Non-steroidal anti-inflammatory drugs",
author = "Emanuela Palmerini and Kunhua Fan and Kan Yang and Mauro Risio and Winfried Edelmann and Martin Lipkin and Guido Biasco",
year = "2007",
month = "11",
language = "English (US)",
volume = "27",
pages = "3807--3812",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice

AU - Palmerini, Emanuela

AU - Fan, Kunhua

AU - Yang, Kan

AU - Risio, Mauro

AU - Edelmann, Winfried

AU - Lipkin, Martin

AU - Biasco, Guido

PY - 2007/11

Y1 - 2007/11

N2 - Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1 +/-/Apc1638N/+ mice, in a preclinical model of human colon cancer. Materials and Methods: Mice were fed AIN-76A diet alone or premixed with piroxicam (60 ppm) for 9 weeks. The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine. Results: Piroxicam reduced the number of tumors per mouse by 80% in the small intestine (0.1 vs. 0.5, p<0.05). In contrast, piroxicam increased tumor incidence (82% vs. 10%, p<0.01), tumor multiplicity (1.2 vs. 0.1, p<0.01) and tumor volume (2.1 vs. 0.2 mm3, p<0.01) in the colon. Apoptosis increased in the epithelium of the small intestine. Conclusion: Consistent with the increased apoptosis, piroxicam reduced tumors in the small intestine. In the cecum, piroxicam increased tumorigenesis but apoptosis was not decreased, suggesting that other mechanisms besides apoptosis are involved in the differential organ-specific effect on tumorigenesis of piroxicam in this colon cancer model.

AB - Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1 +/-/Apc1638N/+ mice, in a preclinical model of human colon cancer. Materials and Methods: Mice were fed AIN-76A diet alone or premixed with piroxicam (60 ppm) for 9 weeks. The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine. Results: Piroxicam reduced the number of tumors per mouse by 80% in the small intestine (0.1 vs. 0.5, p<0.05). In contrast, piroxicam increased tumor incidence (82% vs. 10%, p<0.01), tumor multiplicity (1.2 vs. 0.1, p<0.01) and tumor volume (2.1 vs. 0.2 mm3, p<0.01) in the colon. Apoptosis increased in the epithelium of the small intestine. Conclusion: Consistent with the increased apoptosis, piroxicam reduced tumors in the small intestine. In the cecum, piroxicam increased tumorigenesis but apoptosis was not decreased, suggesting that other mechanisms besides apoptosis are involved in the differential organ-specific effect on tumorigenesis of piroxicam in this colon cancer model.

KW - Apc

KW - Apoptosis

KW - Chemoprevention

KW - Colon cancer

KW - Mlh1

KW - Non-steroidal anti-inflammatory drugs

UR - http://www.scopus.com/inward/record.url?scp=37549006731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549006731&partnerID=8YFLogxK

M3 - Article

C2 - 18225536

AN - SCOPUS:37549006731

VL - 27

SP - 3807

EP - 3812

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -